| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
10-30-2007, 09:22 AM
|
#1 | ||
|
|||
|
In Remembrance
|
Am I closer to understanding why people go berserk after reading this paragraph in an article about Amgen? I think so. But if ever really get to the point of going berserk... I won't be able to move to do it.
Does this make your blood boil or what? In 1994, Amgen made its first acquisition - Synergen Inc., for $262 million through a cash tender offer. The acquisition gave Amgen the patent right to synthetic GDNF or Glial cell line-derived neurotrophic factor developed by Synergen. GDNF was thought to hold great promise for treating Parkinson's disease. However, the much-touted GDNF trial turned out to be a bust as the compound failed to demonstrate any clinical improvement after six months of use and on September 1, 2004, Amgen halted all clinical trials of GDNF. Amgen - Healthy Or Anemic RTT News - Williamsville,NY,USA The acquisition gave Amgen the patent right to synthetic GDNF or Glial cell line-derived neurotrophic factor developed by Synergen. GDNF was thought to hold ...
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
|
 Reply With Quote
|
|
10-30-2007, 10:11 AM
|
#2 | |||
|
||||
|
Senior Member
|
I'm to the point that I think some of us should buy a share of Amgen stock - attend the next shareholders' meeting and tell them to:
SELL the rights to GDNF !!! The sale would add to Amgen's coffers ... and help us!!
__________________
Jean B This isn't the life I wished for, but it is the life I have. So I'm doing my best. |
|||
|
|
Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| The Truth About Adult Cell Therapy | Parkinson's Disease | |||
| McCain Should Know the Truth about Medical Marijuana | ALS News & Research | |||
Truth is irrelevant
Grrrrrrr
Linear Mode
